表皮生长因子受体酪氨酸激酶抑制剂耐药机制研究进展

被引：7

作者：

曹喆

庄亮

陈元

机构：

[1] 华中科技大学同济医学院附属同济医院肿瘤中心

来源：

癌症进展 | 2009年 / 7卷 / 06期

关键词：

非小细胞肺癌; 表皮生长因子受体; 酪氨酸激酶抑制剂;

D O I：

暂无

中图分类号：

R734.2 [肺肿瘤];

学科分类号：

100117 [系统生物医学];

摘要：

含有表皮生长因子受体突变的非小细胞肺癌患者中70%～80%对表皮生长因子受体酪氨酸激酶抑制剂吉非替尼和厄洛替尼敏感,但最终仍会出现耐药导致肿瘤进展。表皮生长因子受体酪氨酸激酶抑制剂耐药分为原发耐药和继发耐药,继发耐药机制主要包括表皮生长因子受体二次突变(T790M)、HER2及HER3的代偿作用、MET扩增、胰岛素样生长因子受体结合蛋白缺失及哺乳动物雷帕霉素靶蛋白信号通路活化。

引用

收藏

页码：622 / 628

页数：7

相关论文

共 9 条

[1]

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins [J].

Guix, Marta ;

Faber, Anthony C. ;

Wang, Shizhen Emily ;

Olivares, Maria Graciela ;

Song, Youngchul ;

Qu, Sherman ;

Rinehart, Cammie ;

Seidel, Brenda ;

Yee, Douglas ;

Arteaga, Carlos L. ;

Engelman, Jeffrey A. .

JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (07) :2609-2619

[2]

Detection of EGFR gene mutations using the wash fluid of CT-guided biopsy needle in NSCLC patients [J].

Otani, Hiroki ;

Toyooka, Shinichi ;

Soh, Junichi ;

Yamamoto, Hiromasa ;

Suehisa, Hiroshi ;

Kobayashi, Naruyuki ;

Gobara, Hideo ;

Mimura, Hidefumi ;

Kiura, Katsuyuki ;

Sano, Yoshifumi ;

Kanazawa, Susumu ;

Date, Hiroshi .

JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (05) :472-476

[3]

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers [J].

Costa, Daniel B. ;

Kobayashi, Susumu ;

Tenen, Daniel G. ;

Huberman, Mark S. .

LUNG CANCER, 2007, 58 (01) :95-103

[4]

Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer [J].

Soh, Junichi ;

Toyooka, Shinichi ;

Aoe, Keisuke ;

Asano, Hiroaki ;

Ichihara, Syuji ;

Katayama, Hideki ;

Hiraki, Akio ;

Kiura, Katsuyuki ;

Aoe, Motoi ;

Sano, Yoshifumi ;

Sugi, Kazuro ;

Shimizu, Nobuyoshi ;

Date, Hiroshi .

INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (10) :2353-2358

[5]

PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients [J].

Endoh, Hideki ;

Yatabe, Yasushi ;

Kosaka, Takayuki ;

Kuwano, Hiroyuki ;

Mitsudomi, Tetsuya .

JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (07) :629-634

[6]

Biological and clinical implications of EGFR mutations in lung cancer [J].

Mitsudomi T. ;

Kosaka T. ;

Yatabe Y. .

International Journal of Clinical Oncology, 2006, 11 (3) :190-198

[7]

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants [J].

Greulich, H ;

Chen, TH ;

Feng, W ;

Jänne, PA ;

Alvarez, JV ;

Zappaterra, M ;

Bulmer, SE ;

Frank, DA ;

Hahn, WC ;

Sellers, WR ;

Meyerson, M .

PLOS MEDICINE, 2005, 2 (11) :1167-1176

[8]

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain [J].

Pao, W ;

Miller, VA ;

Politi, KA ;

Riely, GJ ;

Somwar, R ;

Zakowski, MF ;

Kris, MG ;

Varmus, H .

PLOS MEDICINE, 2005, 2 (03) :225-235

[9]

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib [J].

Pao, W ;

Wang, TY ;

Riely, GJ ;

Miller, VA ;

Pan, QL ;

Ladanyi, M ;

Zakowski, MF ;

Heelan, RT ;

Kris, MG ;

Varmus, HE .

PLOS MEDICINE, 2005, 2 (01) :57-61